The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Stereotactic body radiotherapy was associated with significantly better urinary continence and fewer sexual issues at 2 years ...

Men with localized prostate cancer were randomly assigned to receive either SBRT or control radiotherapy in a phase 3 trial.

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Opening up about their below-the-belt health is not a conversation every man wants to have with his doctor, let alone his ...

Behind breast cancer, prostate cancer is the second most common cancer in the United States. Since its opening in 2012, the ...

Men with prostate cancer diagnosed at an early stage may be able to slow the progression of their disease by adopting a ...

TULSA-PRO is an improvement on long-time prostate cancer treatment that called for radiation or the removal of the entire ...

Prostate cancer is the second-leading cause of cancer death in the United States. Not everyone experiences symptoms, which is ...

New research provides scientific evidence that a healthy diet may reduce the chance of low risk prostate cancer progressing to a more aggressive state in men undergoing active surveillance -- a ...

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

At the moment, patients must request a blood test from their doctor, but Prostate Cancer UK is calling for change.